BVF Partners L.P. is a San Francisco-based private investment partnership founded in 1993 by Mark N. Lampert, specializing in fundamentally-driven investments in small- to mid-cap biotechnology and pharmaceutical companies. The firm employs an active, research-based engagement approach across both private and public biotech investments.
61% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (4 deals in the last 12 months vs 6 prior). Average disclosed round size is $137.7M (across 46 rounds with reported amounts).
Portfolio
47
Fund Size
—
Top Stage
Series B
Last 12 Mo
4
Team
MM
Michael Murray
Managing Director
SL
Spike Loy
Managing Director
TN
Thor Nagel
Biotech Investor
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
54 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Superluminal Medicines | Series B | $60M | Sep 2026 |
| SSuperluminal | Unknown | $60M | Sep 2026 |
 Ambrosia Biosciences Inc. | Series B | $100M | Mar 2026 |
 Third Arc Bio | Series A | $52M | Feb 2026 |
 Sagimet Biosciences | Series C | $175M | Jan 2026 |
 Crescent Biopharma | Growth | $200M | Jun 2025 |
| NNumab Therapeutics | Series C | $55M | Jan 2025 |
 RAPT Therapeutics | Series D | $150M | Dec 2024 |
 Elektrofi | Series C | $112.3M | Oct 2024 |
| AAlpha-9 Oncology, Inc. | Series C | $175M | Oct 2024 |
 Inventiva | Unknown | — | Oct 2024 |
 Pheon Therapeutics | Series B | $120M | May 2024 |
 AltruBio | Series B | $225M | May 2024 |
 Cidara Therapeutics | Unknown | $240M | Apr 2024 |
 Diagonal Therapeutics | Series A | $128M | Apr 2024 |
 Aro Biotherapeutics | Series B | $41.5M | Nov 2023 |
 Forward Therapeutics | Series A | $50M | Nov 2023 |
 Alpha9Tx | Series B | $75M | Dec 2022 |
 Ventus | Series C | $140M | Feb 2022 |
 Nimbus | Unknown | $125M | Jan 2022 |
 ShouTi | Series B | $100M | Jan 2022 |
 Numab | Series C | — | May 2021 |
 Ventus | Series B | $100M | Apr 2021 |
 TYRA Biosciences | Series B | $106M | Mar 2021 |
 Tyra | Series B | $106M | Mar 2021 |
Page 1 of 3
Top Co-Investors
RA Capital Management24 shared
Cormorant Asset Management15 shared
Casdin Capital12 shared
Alexandria Venture Investments12 shared
Perceptive Advisors11 shared
Logos Capital10 shared
Nextech Invest Ltd.8 shared
GV8 shared
Versant Ventures8 shared
Pfizer Ventures8 shared
Andreessen Horowitz7 shared
Samsara BioCapital7 shared
OrbiMed7 shared
Deep Track Capital7 shared
Surveyor Capital7 shared
Forbion6 shared
New Enterprise Associates6 shared
The Invus Group, LLC6 shared
Fonds de solidarité FTQ6 shared
Foresite Capital5 shared
Last updated: 20 October 2026